Aarti Pharmalabs Limited
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Aarti Pharmalabs Limited had its IPO on under the ticker symbol AARTIPHARM.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Aarti Pharmalabs Limited has a staff strength of 2,042 employees.
Shares of Aarti Pharmalabs Limited opened at ₹444 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹420.55 - ₹447.95, and closed at ₹426.1.
This is a -3.37% slip from the previous day's closing price.
A total volume of 449,394 shares were traded at the close of the day’s session.
In the last one week, shares of Aarti Pharmalabs Limited have increased by +6.25%.
Aarti Pharmalabs Limited's Key Ratios
Aarti Pharmalabs Limited has a market cap of ₹0, indicating a price to book ratio of 0 and a price to sales ratio of 0.
In the last 12-months Aarti Pharmalabs Limited’s revenue was ₹0 with a gross profit of ₹0 and an EBITDA of ₹0. The EBITDA ratio measures Aarti Pharmalabs Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Aarti Pharmalabs Limited’s operating margin was 0% while its return on assets stood at 0% with a return of equity of 0%.
In Q0.33333333333333, Aarti Pharmalabs Limited’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Aarti Pharmalabs Limited’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at ₹0 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Aarti Pharmalabs Limited’s profitability.
Aarti Pharmalabs Limited stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 0.
Aarti Pharmalabs Limited stock pays annual dividends of ₹ per share, indicating a yield of None and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- Total Liabilities
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Aarti Pharmalabs Limited ended 2023 with ₹0 in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹0 while shareholder equity stood at ₹0.
Aarti Pharmalabs Limited ended 2023 with ₹0 in deferred long-term liabilities, ₹0 in other current liabilities, in common stock, ₹0 in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹0 and cash and short-term investments were ₹0. The company’s total short-term debt was ₹0 while long-term debt stood at ₹0.
Aarti Pharmalabs Limited’s total current assets stands at ₹0 while long-term investments were ₹0 and short-term investments were ₹0. Its net receivables were ₹0 compared to accounts payable of ₹0 and inventory worth ₹0.
In 2023, Aarti Pharmalabs Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹0.
Comparatively, Aarti Pharmalabs Limited paid ₹0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Aarti Pharmalabs Limited stock is currently trading at ₹426.1 per share. It touched a 52-week high of ₹457 and a 52-week low of ₹457. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹367.38 and 200-day moving average was ₹0 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Aarti Pharmalabs Limited
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Aarti Pharmalabs Limited primarily engages in the manufacture and sale of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates in India and internationally. Its APIs and intermediates are used in various therapeutic areas, including anti-hypertensive, anti-asthmatic, anti-cancer, central nervous system (CNS) agents, skincare, decongestant, cardiovascular, anti-thalassemic, analgesic, anti-diabetic, and ophthalmologic medications. The company also develops new chemical entities (NCE), regulatory starting materials (RSM), basic starting materials, key starting materials (KSM), key building blocks, xanthine derivatives, and allied products. In addition, it provides contract development and manufacturing services for drug substance projects comprising NCEs, APIs, RSMs, and Intermediates for innovator pharmaceutical and biotech companies internationally. The company was formerly known as Aarti Organics Limited. Aarti Pharmalabs Limited was incorporated in 2019 and is based in Mumbai, India.